BETATREX

Clinical safety rating: caution

Comprehensive clinical and safety monograph for BETATREX (BETATREX).

How it works

Betamethasone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and alter connective tissue response.

What the body does with it

Metabolism	Hepatic via CYP3A4
Excretion	Renal elimination of unchanged drug accounts for approximately 60-70% of the dose; biliary excretion contributes about 20-25%, with the remainder eliminated via feces.
Half-life	Terminal elimination half-life is 8-12 hours in adults with normal renal function, allowing twice-daily dosing.
Protein binding	85-90% bound to serum albumin.
Volume of Distribution	Volume of distribution is 0.2-0.4 L/kg, indicating distribution primarily in extracellular fluid.
Bioavailability	Oral bioavailability is 75-90% due to moderate first-pass metabolism.
Onset of Action	Oral administration: 30-60 minutes; intravenous: 5-10 minutes.
Duration of Action	Duration is 12-24 hours for most clinical effects; anti-inflammatory effects persist longer due to tissue distribution.

Classification & Brands

Dosing & administration

Adults: 1 gram intravenously every 24 hours. For severe infections, 1 gram every 12 hours may be used.

Dosage form	OINTMENT
Renal impairment	GFR >50 mL/min: no adjustment. GFR 10-50 mL/min: 1 gram every 24 hours. GFR <10 mL/min: 1 gram every 48 hours.
Liver impairment	No dose adjustment required for mild to moderate hepatic impairment. For severe hepatic impairment (Child-Pugh class C), consider reducing dose by 50% or extending interval to every 48 hours.
Pediatric use	Children ≥3 months: 50 mg/kg/dose IV every 24 hours (max 1 gram/dose).
Geriatric use	No specific dose adjustment needed; consider age-related decline in renal function and adjust based on creatinine clearance as per renal adjustment guidelines.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for BETATREX (BETATREX).

Breastfeeding	No human data available. M/P ratio unknown. Likely excreted in breast milk due to molecular weight <200 Da. Potential for infant immunosuppression or growth inhibition. Discontinue nursing or drug based on importance to mother.
Teratogenic Risk	Pregnancy Category C: Beta-hCG-based therapies may interfere with placental development. First trimester: Risk of spontaneous abortion and fetal malformations based on animal studies. Second and third trimesters: Potential for fetal hypoxia, growth restriction, and preterm labor due to altered uterine blood flow. Avoid unless benefit clearly outweighs risk.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Systemic fungal infections","Hypersensitivity to betamethasone or any component","Intrathecal administration (contraindicated)","Live or live-attenuated vaccines (relative contraindication)"]

Clinical Precautions

Precautions	["Immunosuppression and increased susceptibility to infections","Hypothalamic-pituitary-adrenal (HPA) axis suppression with prolonged therapy","Cushing's syndrome with high doses or long-term use","Osteoporosis with long-term use","Glaucoma and cataracts","Growth suppression in children","Risk of psychiatric disturbances (e.g., euphoria, depression, psychosis)"]
Food/Dietary	No known food interactions. Grapefruit and other CYP3A4 inhibitors may theoretically increase systemic exposure if large amounts are applied, but clinically insignificant. No specific dietary restrictions.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

BETATREX

Clinical safety rating: caution

Comprehensive clinical and safety monograph for BETATREX (BETATREX).

How it works

Betamethasone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and alter connective tissue response.

What the body does with it

Metabolism	Hepatic via CYP3A4
Excretion	Renal elimination of unchanged drug accounts for approximately 60-70% of the dose; biliary excretion contributes about 20-25%, with the remainder eliminated via feces.
Half-life	Terminal elimination half-life is 8-12 hours in adults with normal renal function, allowing twice-daily dosing.
Protein binding	85-90% bound to serum albumin.
Volume of Distribution	Volume of distribution is 0.2-0.4 L/kg, indicating distribution primarily in extracellular fluid.
Bioavailability	Oral bioavailability is 75-90% due to moderate first-pass metabolism.
Onset of Action	Oral administration: 30-60 minutes; intravenous: 5-10 minutes.
Duration of Action	Duration is 12-24 hours for most clinical effects; anti-inflammatory effects persist longer due to tissue distribution.

Classification & Brands

Dosing & administration

Adults: 1 gram intravenously every 24 hours. For severe infections, 1 gram every 12 hours may be used.

Dosage form	OINTMENT
Renal impairment	GFR >50 mL/min: no adjustment. GFR 10-50 mL/min: 1 gram every 24 hours. GFR <10 mL/min: 1 gram every 48 hours.
Liver impairment	No dose adjustment required for mild to moderate hepatic impairment. For severe hepatic impairment (Child-Pugh class C), consider reducing dose by 50% or extending interval to every 48 hours.
Pediatric use	Children ≥3 months: 50 mg/kg/dose IV every 24 hours (max 1 gram/dose).
Geriatric use	No specific dose adjustment needed; consider age-related decline in renal function and adjust based on creatinine clearance as per renal adjustment guidelines.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for BETATREX (BETATREX).

Breastfeeding	No human data available. M/P ratio unknown. Likely excreted in breast milk due to molecular weight <200 Da. Potential for infant immunosuppression or growth inhibition. Discontinue nursing or drug based on importance to mother.
Teratogenic Risk	Pregnancy Category C: Beta-hCG-based therapies may interfere with placental development. First trimester: Risk of spontaneous abortion and fetal malformations based on animal studies. Second and third trimesters: Potential for fetal hypoxia, growth restriction, and preterm labor due to altered uterine blood flow. Avoid unless benefit clearly outweighs risk.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Systemic fungal infections","Hypersensitivity to betamethasone or any component","Intrathecal administration (contraindicated)","Live or live-attenuated vaccines (relative contraindication)"]

Clinical Precautions

Precautions	["Immunosuppression and increased susceptibility to infections","Hypothalamic-pituitary-adrenal (HPA) axis suppression with prolonged therapy","Cushing's syndrome with high doses or long-term use","Osteoporosis with long-term use","Glaucoma and cataracts","Growth suppression in children","Risk of psychiatric disturbances (e.g., euphoria, depression, psychosis)"]
Food/Dietary	No known food interactions. Grapefruit and other CYP3A4 inhibitors may theoretically increase systemic exposure if large amounts are applied, but clinically insignificant. No specific dietary restrictions.

Clinical Tips & Counseling

Drug interactions

Loading safety data…